Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
AssigneeEli Lilly and Company
InventorsRichard DiMarchi, Suad Efendic
Life of this patent
Estimating the term…
Abstract
This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.
Claims14
A method of reducing body weight by administering to a subject a composition comprising a glucagon-like peptide-1, or an analog or derivative thereof.
A method of reducing body weight, comprising, administering to a subject a composition comprising a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives, agonists of the GLP-1 receptor, agonists of the GLP-1 signal transduction cascade, compounds that stimulate synthesis of endogenous GLP-1, compounds that stimulate release of endogenous GLP-1, and pharmaceutically-acceptable salts thereof, in a dose sufficient to cause reduction in body weight.
A method of reducing body weight, comprising, administering to a subject a composition comprising a compound selected from the group consisting of agonists of the GLP-1 receptor, agonists of the GLP-1 signal transduction cascade, compounds that stimulate synthesis of endogenous GLP-1, compounds that stimulate release of endogenous GLP-1, and pharmaceutically-acceptable salts thereof, in a dose sufficient to cause reduction in body weight.
A composition used for the reduction of body weight, said composition comprising a glucagon-like peptide-1, or an analog, derivative, or active fragment thereof.
Dependencies are inferred from the claim text.